Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has announced the retirement of Dr John Fara, the company's chairman, president and CEO. Dr Fara will continue to serve Depomed as a director and a consultant.
Subscribe to our email newsletter
Carl Pelzel has been appointed president and CEO and to the company's board of directors. Mr Pelzel has been Depomed's executive vice president and COO since 2005.
Craig Smith has been appointed chairman of the company's board of directors. Dr Smith has been a member of the company's board since 2004.
Dr Fara commented: “Over the past eleven years, the company completed its IPO, developed and commercialized Glumetza and Proquin XR, moved Gabapentin GR into Phase III clinical trials and established our drug delivery technology as a standard in the industry. I have worked with Carl for the past two years and believe his experience and energy will accelerate Depomed's transition to a fully integrated specialty pharmaceutical company.”